Please login to the form below

Vimpat

This page shows the latest Vimpat news and features for those working in and with pharma, biotech and healthcare.

UCB bags FDA approval for epilepsy drug Briviact

Belgium-headquartered UCB is already an established player in epilepsy with drugs such as Vimpat (lacosamide) and Keppra (levetiracetam), which is off-patent in most major markets. ... Vimpat added another 495m.

Latest news

UCB wins European approval for epilepsy drug Briviact

The drug adds to an epilepsy treatment portfolio at UCB currently represented by Vimpat (lacosamide) - with sales of 495m in the first nine months of 2015 - along with Keppra (levetiracetam) which
UCB boosted by core medicines growth

Revenue was boosted by its core product range, with Crohn's disease and psoriatic arthritis treatment Cimzia (certolizumab pegol); epilepsy medicine Vimpat (lacosamide) and Parkinson's disease and restless leg syndrome ... Sales of Vimpat increased by 15%
UCB submits brivaracetam for use in epilepsy

The company has since turned to other drugs in its epilepsy portfolio, including Vimpat (lacosamide). ... At the end of last year UCB announced a partnership with Daiichi Sankyo to bring Vimpat to Japan.
New UCB CEO Jean-Christophe Tellier expands his executive team

Hands new roles to Emmanuel Caeymaex, Bharat Tewarie and Jeff Wren
UCB partners with Daiichi to bring epilepsy drug to Japan

UCB partners with Daiichi to bring epilepsy drug to Japan. Companies partner on expanding market for Vimpat. ... Vimpat is an important drug for UCB as it looks to overcome the loss in revenue due to the loss of patent protection for older anti-epileptic

More from news
Approximately 8 fully matching, plus 14 partially matching documents found.

Latest Intelligence

Pharma deals during November 2013

Certainly the good performances from key products such as Cimzia, Vimpat and Neupro may well appeal to those companies feeling a little pipeline bereft.
VIDEO interview: Neil Weir, UCB

For UCB, this notion is especially important considering its focus on severe diseases, including the recent launches of Cimzia (certolizumab pegol) for rheumatoid arthritis and Crohn's disease; Vimpat (lacosamide) for ... As for the future of the company,
Interview with Roch Doliveux, UCB

It is the same with Vimpat. Peak sales were once 350m; now, estimates are at least 1.2bn. ... Vimpat treats a subset of epilepsy, partial onset seizures. One in three patients has this refractory type of seizure.

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

Featured jobs

Engagement Strategist, Healthcare Brand Communications, London, ...: Circa £60K

Head of Operations/ BUD, Healthcare PR, London – Excellent leade...: Excellent Package

Senior Account Manager / Account Director: Great salary and bebefits

Science writer, Healthcare Brand Communications, London, £45-50K...: £45-50K

Editorial Director – Medical Education – Oxford: Negotiable

Medical Writer - (London, Brighton or Copenhagen): Competitive

Project Manager, Medical Communications, Oxford: Excellent Salary

Senior Account Manager or AD - Medical Communications: Salary TBC

Senior Medical Writer, Medical Communications, Relocate to Cardi...: Excellent Salary

Account Manager, Healthcare PR: £40, 000 – £42, 000 great benefits and bonuses

Senior Medical Writer: Great salary and bebefits

Senior Programme Executive: Salary TBC

FREELANCE OPPORTUNITIES!!!!! Medical Education - Healthcare Adve...: EXCELLENT DAY RATES AVAILABLE

Account Manager – Med Comms – London: Salary TBC

Editor > Senior Editor – Medical Education – London: Very competitive with excellent benefits

Editorial Team Leader or Scientific Director: £50, 000 - £55, 000 benefits

Editor – Medical Education Agency – Bucks: Salary TBC

Scientific Director: Great salary and bebefits

Senior / Principal Regulatory Writer – Home Working - UK or US: HIGHLEY COMPETATIVE SALARY, BONUS &BENEFITS

Digital Senior Account Director – Healthcare Advertising – Londo...: Salary TBC

HOME BASED Senior Account Executive / Account Manager - Medical ...: Salary TBC

Senior Account Director, Healthcare Brand Communications, London: Excellent Package

Senior Medical Writer: Great salary and benefits

Medical Writer, e-learning/ training, London: Excellent Salary

Senior Account Manager – Med Comms – Kent: Salary TBC

Subscribe to our email news alerts

PMHub

Add my company

M3 (EU)

M3 was founded in 2000 with the goal of changing the world of medicine through making full use of the...

Latest intelligence

Why heading online for scientific meetings can yield greater HCP engagement: Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance: Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies: Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...